학술논문
Results of a randomized double-blind placebo-controlled Phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy
Document Type
Article
Author
Source
In Kidney International January 2024 105(1):189-199
Subject
Language
ISSN
0085-2538